Therefore, our objective is to conduct an updated systematic review and meta‐analysis of covariate‐adjusted real‐world studies to evaluate the impact of preadmission/prediagnosis use of GLP‐1 receptor agonists on the risk of mortality in patients with COVID‐19 and diabetes. Here, GLP1R is linked to COVID-19.